In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.
The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
Lidia Schapira, MD, FASCO, professor of medicine at Stanford Medicine, medical oncologist, and director for the Stanford Cancer Institute and the Stanford Comprehensive Cancer Center, discusses the ...
HR+/HER2- breast cancer involves cells that test positive for hormone receptors and negative for HER2 proteins. It's the most ...
1don MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone ...
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...
The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...
East Harris County has elevated levels of cervix uteri, leukemia, lung and bronchus, and lymphoma cancers, the Texas ...
Laura Wharam had a double mastectomy but 4 years later her breast cancer returned and metastasized, spreading to her liver, ...
Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for select patients.
More widespread use of mammograms, along with the implementation of targeted hormone therapies more than 40 years ago, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results